Lee Tien-Li's Form 4 filing
Aardvark Therapeutics, Inc. (AARD) · filed Sep 12, 2025
- Accession no.
- 0001193125-25-202490
- Filed
- Sep 12, 2025
- Trade date
- Sep 10-12, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $160.6K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee Tien-LiCIK 0001940120 | Director, Officer (Chief Executive Officer), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | Common Stock | PPurchaseAcquired | +9,000 | $7.91F1 | +$71,190 | 1,522,384 | Direct | |
| Sep 11, 2025 | Common Stock | PPurchaseAcquired | +6,000 | $7.82F2 | +$46,920 | 1,528,384 | Direct | |
| Sep 12, 2025 | Common Stock | PPurchaseAcquired | +5,000 | $8.50F3 | +$42,500 | 1,533,384 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.84 to $7.95 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F2
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $7.8135 to $7.825 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $8.4199 to $8.69 per share, inclusive. The reporting person undertakes to provide Aardvark Therapeutics, Inc. ("Aardvark"), any security holder of Aardvark, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.